High Growth Tech Stocks In Hong Kong To Watch

Despite recent declines in global markets and economic slowdown concerns, Hong Kong's tech sector continues to be a focal point for investors seeking high-growth opportunities. With the Hang Seng Index experiencing fluctuations, it's crucial to identify stocks that demonstrate strong fundamentals and resilience in volatile market conditions.

Top 10 High Growth Tech Companies In Hong Kong

Name	Revenue Growth	Earnings Growth	Growth Rating
Wasion Holdings	22.37%	25.47%	★★★★★☆
MedSci Healthcare Holdings	48.74%	48.78%	★★★★★☆
Inspur Digital Enterprise Technology	25.37%	39.10%	★★★★★☆
Cowell e Holdings	31.82%	35.43%	★★★★★★
Innovent Biologics	21.45%	59.82%	★★★★★☆
RemeGen	26.30%	52.19%	★★★★★☆
Akeso	32.82%	54.95%	★★★★★★
Sichuan Kelun-Biotech Biopharmaceutical	24.70%	8.53%	★★★★★☆
Biocytogen Pharmaceuticals (Beijing)	21.53%	109.17%	★★★★★☆
Beijing Airdoc Technology	37.47%	93.35%	★★★★★☆

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Kuaishou Technology (SEHK:1024)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kuaishou Technology, an investment holding company, offers live streaming, online marketing, and other services in the People’s Republic of China with a market cap of HK$168.81 billion.

Operations: The company generates revenue primarily from domestic operations, amounting to CN¥117.32 billion, with overseas operations contributing CN¥3.57 billion. The primary services include live streaming and online marketing within the People's Republic of China.

Kuaishou Technology's recent earnings report highlights robust growth, with Q2 sales reaching ¥30.98 billion, up from ¥27.74 billion year-over-year. Net income surged to ¥3.98 billion compared to last year's ¥1.48 billion, reflecting a significant improvement in profitability. The company's investment in R&D is notable, spending 9% of revenue on innovation to enhance its AI capabilities like Kling AI and Kolors models, which are crucial for future expansion and user engagement enhancement. The introduction of subscription tiers for Kling AI aligns with the industry's shift towards SaaS models, ensuring recurring revenue streams and better monetization of their advanced video generation technology. With earnings forecasted to grow at 18.8% annually over the next few years and a strong focus on enhancing user experience through continuous upgrades in their AI offerings, Kuaishou is well-positioned to capitalize on the growing demand for innovative content creation tools in both local and international markets.

• Click to explore a detailed breakdown of our findings in Kuaishou Technology's health report.

• Gain insights into Kuaishou Technology's historical performance by reviewing our past performance report.

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs to address unmet medical needs in China and internationally with a market cap of HK$38.66 billion.

Operations: Kelun-Biotech generates revenue primarily from its pharmaceuticals segment, amounting to CN¥1.88 billion. The company focuses on the research and development, manufacturing, and commercialization of novel drugs in China and internationally.

Sichuan Kelun-Biotech Biopharmaceutical's revenue surged by 24.7% over the past year, driven by robust demand for its innovative therapies. The company has shown promising results in recent clinical trials, notably with sac-TMT demonstrating a median progression-free survival of 5.6 months versus 2.7 months in TNBC patients treated with TPC. Investing heavily in R&D, Sichuan Kelun allocated approximately ¥1 billion to research activities last year, underscoring their commitment to innovation and future growth prospects within the biotech sector.

• Unlock comprehensive insights into our analysis of Sichuan Kelun-Biotech Biopharmaceutical stock in this health report.

• Assess Sichuan Kelun-Biotech Biopharmaceutical's past performance with our detailed historical performance reports.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$48.23 billion.

Operations: The company focuses on the research, development, production, and sale of biopharmaceutical products, generating CN¥1.87 billion in revenue from these activities.

Akeso's recent earnings report reveals a significant drop in revenue from ¥3.68 billion to ¥1.02 billion, coupled with a net loss of ¥238.59 million compared to last year's net income of ¥2.53 billion. Despite this, the company is making strides in innovative therapies like ivonescimab, which has shown superior efficacy over pembrolizumab in Phase III trials for NSCLC patients with positive PD-L1 expression. With R&D expenses reaching approximately 32.8% of total revenue and expected annual profit growth forecasted at 54.95%, Akeso demonstrates a strong commitment to advancing its biotech portfolio amidst challenging financial metrics.

• Navigate through the intricacies of Akeso with our comprehensive health report here.

• Evaluate Akeso's historical performance by accessing our past performance report.

Key Takeaways

• Reveal the 45 hidden gems among our SEHK High Growth Tech and AI Stocks screener with a single click here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com